Teva has talked up its biosimilars business as a future growth driver for the company, following a successful US launch of Truxima (rituximab-abbs) – in partnership with Celltrion – that has seen the Rituxan rival capture a fifth of the market in a year, in part due to its exclusive rheumatoid arthritis indication.
Truxima Hits 20% Share For Teva
Rheumatoid Arthritis Indication Helps Rituximab Biosimilar Gain Ground In US
Teva says the Truxima rituximab biosimilar it sells in the US in partnership with Celltrion has captured a fifth of the market a year after launch, driven in part by its exclusive rheumatoid arthritis indication.
